Biodegradable Ionizable Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA delivery technologies face challenges in efficiently delivering mRNA to cells, particularly hard-to-transfect cells, and there is a need for biodegradable ionizable lipids that can facilitate intramuscular and intravenous administration for effective mRNA delivery.
Innovation Solution
Development of biodegradable ionizable lipids that form efficient delivery vehicles for mRNA, suitable for in vivo, in vitro, and ex vivo transfection, including formulations that enhance intramuscular and intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional non-viral nanoparticles are used for mRNA delivery, then delivery capability is achieved, but transfection efficiency to hard-to-transfect cells is insufficient
Solution Approach 1:
The patent modifies the chemical parameters of the lipid molecules by incorporating ionizable fatty acid tails with specific pKa values (5-7.5) and controlled chain lengths (12-24 carbons), transforming the lipid properties to enhance membrane interaction and endosomal escape, thereby improving transfection efficiency to hard-to-transfect cells
Solution Approach 2:
The invention creates composite lipid nanoparticle formulations combining ionizable lipids with specific mRNA sequences and adjuvants, where the composite structure enables synergistic effects that improve delivery reliability and transfection efficiency simultaneously
2Ease of operation
If lipid nanoparticle formulations are used for mRNA delivery, then intramuscular and intravenous administration is enabled, but liver and spleen accumulation occurs
Solution Approach 1:
The patent introduces local quality variations through ionizable lipid molecules that exhibit different properties at different locations: neutral at physiological pH for stable circulation, but ionizable at endosomal pH for targeted release, thereby enabling ease of administration while minimizing harmful accumulation in liver and spleen
Solution Approach 2:
The ionizable lipid molecules dynamically change their charge state based on environmental pH, transitioning from neutral in circulation to protonated in endosomes, enabling the formulation to adapt its behavior for optimal delivery while avoiding harmful accumulation
3Reliability
If existing mRNA delivery vehicles are used, then protein replacement and immunomodulation are achieved, but biodegradability is insufficient
Solution Approach 1:
The patent selects ionizable fatty acids with specific chain lengths (12-24 carbons) and pKa values (5-7.5) that optimize both delivery effectiveness and biodegradability, allowing the lipid to be sufficiently stable during circulation but readily degraded by esterases in target cells
Solution Approach 2:
The ionizable lipid molecules are designed as temporary carriers that perform their delivery function and then are rapidly degraded and eliminated, avoiding long-term accumulation while maintaining effective delivery capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable ionizable lipids demonstrate high efficiency in transfecting cells, including hard-to-transfect cells, and induce robust immune responses, with minimal liver and spleen accumulation, making them suitable for mRNA-based vaccines and therapies.
Implementation Method 1
biodegradable ionizable lipids that, when incorporated in formulations containing mRNA, demonstrate efficient in vivo transfection
Implementation Method 2
efficient in vivo transfection, for example, via either intramuscular (IM) or intravenous (IV) administration
Implementation Method 3
efficient in vivo transfection, for example, via either intramuscular (IM) or intravenous (IV) administration
Implementation Method 4
The lipids provided herein are also suitable for in vitro and ex vivo transfection of mRNA to hard-to-transfect cells
Data Source
AI summary
Provided herein are compounds, such as compounds of Formulae (I), (I′), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I′), (XI), (XII), (XIII), and (VIII).